FindTrial
Sign In

Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)

Evaluation of the Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05966025
Acronym
MAFLD
Enrollment
60
Registered
2023-07-28
Start date
2023-12-28
Completion date
2025-12-31
Last updated
2023-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver Disease, Fatty Liver

Keywords

Itopride in Mafld

Brief summary

Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD

Detailed description

the study will evaluate the possible benefits of itopride when added to pateints with metabolic associated fatty liver disease

Interventions

DRUGItopride

itopride will be taken by pateints one time per day by dose 100 mg

DRUGconventional therapy

will taken by patient in control group

Sponsors

Beni-Suef University
CollaboratorOTHER
October 6 University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patients presented to hepatology clinic . -Patients are diagnosed by ultrasonography and laboratory tests for liver and lipids. - - * Patients with comorbidites like hypertension,diabetes,dyslipidemia

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
incidence of MAFLD1 Year Highly sensitive CRP in mg\\L by ELIZA, Fibro scan in MHzby fibroscan apparatus, ALT,AST in unit\\liter by blood test

Secondary

MeasureTime frameDescription
Incidence of mafld 1 YearDecrease LDL in mg\\dl, Triglyceride and total cholesterolin mg\\dl ,HOMA-IR in mg\\dl, IL6,TNF alpha in mg\\l by eliza

Countries

Egypt

Contacts

Primary ContactMaha y fekry, beclore
maha.youssif.ph@o6u.edu.eg01111349592
Backup ContactEngy ah wahsh, Lecturer
engywahsh@o6u.edu.eg01003095692

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026